Back to Search Start Over

Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: a retrospective cohort study.

Authors :
Patel, Vishal
Yarwood, Marcus J.
Levick, Bethany
Gibbons, Daniel C.
Drysdale, Myriam
Kerr, William
Watkins, Jonathan D.
Young, Sophie
Pierce, Benjamin F.
Lloyd, Emily J.
Birch, Helen J.
Kamalati, Tahereh
Brett, Stephen J.
Source :
Current Medical Research & Opinion; Aug2024, Vol. 40 Issue 8, p1323-1334, 12p
Publication Year :
2024

Abstract

To describe characteristics and acute clinical outcomes for patients with COVID-19 treated with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or untreated patients at highest risk per National Health Service (NHS) criteria. Retrospective study of non-hospitalized patients between 1 December 2021 and 31 May 2022, using data from the Discover-NOW dataset (North-West London). Included patients were aged ≥12 years and treated with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or untreated but expected to be eligible for early treatment per NHS highest-risk criteria. COVID-19-related and all-cause hospitalizations were reported for 28 days from COVID-19 diagnosis (index). Subgroup analyses were conducted in patients with advanced renal disease, those aged 18–64 and ≥65 years, and by period of Omicron BA.1, BA.2 and BA.5 (post-hoc exploratory) predominance. Overall, 1503 treated and 4044 eligible high-risk untreated patients were included. A high proportion of patients on sotrovimab had advanced renal disease (29.3%), ≥3 high-risk comorbidities (47.6%) and were aged ≥65 years (36.9%). Five of 696 (0.7%) patients on sotrovimab, <5/337 (0.3–1.2%) on nirmatrelvir/ritonavir, 10/470 (2.1%) on molnupiravir and 114/4044 (2.8%) untreated patients were hospitalized with COVID-19. Similar results were observed across all subgroups. The proportion of patients dying within 28 days of the index period was similarly low across all cohorts (<2%). Patients receiving sotrovimab appeared to show evidence of multiple high-risk comorbidities. Low hospitalization rates were observed for all treated cohorts across subgroups and periods of predominant variants of concern. These results require confirmation with comparative effectiveness analyses adjusting for differences in underlying patient characteristics. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03007995
Volume :
40
Issue :
8
Database :
Complementary Index
Journal :
Current Medical Research & Opinion
Publication Type :
Academic Journal
Accession number :
178880843
Full Text :
https://doi.org/10.1080/03007995.2024.2376144